Valeant Pharmaceuticals International Inc. (NYSE:VRX)‘s stock had its “sector perform” rating restated by equities researchers at RBC Capital Markets in a research note issued on Tuesday.

VRX has been the subject of a number of other research reports. Mizuho reiterated a “sell” rating on shares of Valeant Pharmaceuticals International in a research note on Tuesday, May 31st. Morgan Stanley reiterated a “positive” rating on shares of Valeant Pharmaceuticals International in a research note on Friday, August 19th. Rodman & Renshaw reiterated a “buy” rating and issued a $90.00 target price on shares of Valeant Pharmaceuticals International in a research note on Thursday, July 28th. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Valeant Pharmaceuticals International in a research note on Monday, June 27th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $28.00 target price on shares of Valeant Pharmaceuticals International in a research note on Wednesday, August 10th. Six investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Hold” and an average price target of $56.09.

Valeant Pharmaceuticals International (NYSE:VRX) traded down 2.196% on Tuesday, reaching $26.505. The company’s stock had a trading volume of 9,114,700 shares. Valeant Pharmaceuticals International has a 52 week low of $18.55 and a 52 week high of $225.54. The company’s market capitalization is $9.21 billion. The firm’s 50 day moving average price is $27.50 and its 200-day moving average price is $29.38.

Valeant Pharmaceuticals International (NYSE:VRX) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.48 by $0.08. The firm had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.47 billion. Valeant Pharmaceuticals International had a positive return on equity of 46.59% and a negative net margin of 9.29%. The business’s revenue was down 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.14 earnings per share. On average, equities analysts predict that Valeant Pharmaceuticals International will post $6.54 EPS for the current year.

In other Valeant Pharmaceuticals International news, Director Argeris N. Karabelas bought 4,000 shares of the stock in a transaction that occurred on Thursday, August 11th. The shares were purchased at an average cost of $24.65 per share, for a total transaction of $98,600.00. Following the transaction, the director now directly owns 20,726 shares in the company, valued at $510,895.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 16.37% of the stock is owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc boosted its position in shares of Valeant Pharmaceuticals International by 2.8% in the first quarter. Legal & General Group Plc now owns 1,209,137 shares of the specialty pharmaceutical company’s stock valued at $31,830,000 after buying an additional 33,247 shares during the period. Okumus Fund Management Ltd. boosted its position in shares of Valeant Pharmaceuticals International by 98.5% in the first quarter. Okumus Fund Management Ltd. now owns 3,722,464 shares of the specialty pharmaceutical company’s stock valued at $97,901,000 after buying an additional 1,846,864 shares during the period. LPL Financial LLC boosted its position in shares of Valeant Pharmaceuticals International by 65.5% in the first quarter. LPL Financial LLC now owns 91,050 shares of the specialty pharmaceutical company’s stock valued at $2,616,000 after buying an additional 36,046 shares during the period. Seven Eight Capital LLC purchased a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $374,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Valeant Pharmaceuticals International during the first quarter valued at about $1,728,000. Hedge funds and other institutional investors own 63.60% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.